SlideShare une entreprise Scribd logo
1  sur  55
Chamber
Enlargement &
Hypertrophy
Role of ECG
• ECG is a simple, readily available and inexpensive tool for the
detection of cardiac chamber enlargement
• Can provide useful clues or arouse suspicion of underlying cardiac
condition
• Most ECCG criteria have low sensitivity but high specificity
• Clinical correlates and prognostic significance
• Screening and population based studies
Chamber Enlargement & Hypertrophy 2
General Principles
• Enlargement of the cardiac Chambers may manifest on the ECG as
an alteration of
• Waveform morphology
• Amplitude / Voltage
• Axis
• Duration (widening)
• These applied to both the p waves and the QRS complex
• Atrial abnormalities may suggest corresponding ventricular
hypertrophy
Chamber Enlargement & Hypertrophy 3
Limitations
• Enlargement? hypertrophy? dilatation?
• Voltage criteria can carry significantly based on
• Age
• Gender
• Race
• Habitus (chest wall thickness/abnormalities )
• Pulmonary/pericardial pathology
Chamber Enlargement & Hypertrophy 4
Before commenting
• Assess technical quality of ECG
• Placement of the electrolytes (especially precordial)
• Voltage standardisation (1 mm=0.1 millivolt)
• SPEED of recording (can affect measurement of duration)
• Preferable to express voltage in millivolts (mV) rather than millimeter (mm)
Chamber Enlargement & Hypertrophy 5
Atrial abnormalities
Atrial dilatation, hypertrophic, elevated atrial pressures, impaired ventricular
distensibility, and delayed intra-atrial conduction produced similar changes
on ECG and cannot be differentiated
As such, the terms of left atrial abnormality in right atrial abnormality or
preferably to left / right atrial enlargement, the mitrale / congenitale /
pulmonale
Chamber Enlargement & Hypertrophy 6
‘P’ wave
Chamber Enlargement & Hypertrophy 8
P wave reflects atrial
depolarisation
Right atrial activation begins first.
Proceeds from the SAN into
(sinoatrial node) in the inferior
and the anterior direction and is
reflected by ascending limb of the
p wave in the frontal plane leads.
Chamber Enlargement & Hypertrophy 9
Left atrial activation begins 0.03
seconds after the right atrial
activation.
Proceeds from high in the
interatrial septum (IAS) in a left,
inferior and posterior direction.
Constitute distal half of the
descending limb of the p wave.
Normal ‘P’ wave
LEAD II
Duration in lead II is 0.08 - 0.1 second,
Max 0. 11 second.
Amplitude in lead: Usually 2 mm, max
2.5 mm.
Chamber Enlargement & Hypertrophy 10
LEAD V1
Usually biphasic.
Initial positive movement deflection < 1.5
mm
Terminal negative deflection not exceeding 1
mm in-depth and < 0.03 seconds in duration.
Duration of p wave in V1 is 0.05-0.08
second.
Left atrial abnormalities
3 basic ECG changes:
1. Prolongation and delay of the terminal or left atrial component of atrial
activation (Bachmann’s bundle).
2. Increased posterior deviation of left atrial vector
3. Left axis deviation of main manifest frontal plane p wave axis.
Chamber Enlargement & Hypertrophy 11
Criteria for LAA
LEAD II
Chamber Enlargement & Hypertrophy 12
LEAD V1 – P terminal force (MORRIS
Index)
• Ratio between the duration of p wave in lead II and the PR
segment of >1.6 (Marcuz Index)
• Leftward shift of the p wave axis less than 15-30°
ECHOCARDIOGRAPHIC
EVALUATION
OF ECG CRITERIA FOR LAA
CRITERA SENSITIVITY SPECIFICITY
Terminal negative P in V1 >0.04 mm-sec 83 80
Duration between peak of P Wave notches > 0.04 s 15 100
P wave duration >0.11 s 31 64
Ratio of P wave duration to PR segment> 1.6 31 64
Amplitude of terminal -ve P wave deflection in V1 > 0.1mv 60 93
Chamber Enlargement & Hypertrophy 13
CAUSES OF LA ABNORMALITY
• Valvular heart disease, mainly mitral and aortic
• Hypertensive heart disease
• Cardiomyopathy (dilated/ restrictive/hypertrophic)
• CAD
Chamber Enlargement & Hypertrophy 14
• The term P mitrale refers to a P wave that is abnormally notched and wide because this P wave is
commonly seen in patients with mitral valve disease, particularly mitral stenosis.
Chamber Enlargement & Hypertrophy 15
• The mere presence of a twin-peaked P wave is not diagnostic of LA abnormality
Chamber Enlargement & Hypertrophy 16
Right atrial abnormalities
LEAD II
• Total p wave duration is usually normal.
• Peaked p waves with amplitudes in lead to more than 0.25 millivolts
(even a normal amplitude p wave if pointed)
LEAD V1
• Prominent initial positivity of the P wave in V1 or V2 (>0.15 mV)
• Initial area under curve >0.06 mm-sec qR complex, namely a small q
followed by a large R wave, usually in tricuspid regurgitation
• Low-amplitude (<0.6 mV) QRS complexes in lead V1 with a threefold
or greater increase in lead V2
Chamber Enlargement & Hypertrophy 17
Change in ‘P’ axis
• In acquired heart disease (e.g. COPD), rightward shift of the
mean P wave axis to above +75 degrees – ‘P pulmonale’
• In congenital heart disease, the axis is normal or to left (-40
to +70 degrees) – ‘P congenitale’
Chamber Enlargement & Hypertrophy 18
Kaplan Criteria
• QRS axis> 90°
• P amplitude in V2> 0.15mv
• R/S> 1 in V1 in the absence of RBBB
• Combined sensitivity of 49% with specificity of 100%
Chamber Enlargement & Hypertrophy 19
CAUSES OF RA ABNORMALITY
• Congenital heart disease (Ebstein's anomaly, severe PS)
• Tricuspid valve disease
• Chronic cor pulmonale (COPD)
RAA is very uncommon in isolated ASD without PH.
Chamber Enlargement & Hypertrophy 20
• Tall, peaked ("gothic") P wave in leads IIL, IIL, and aVF ,P axis> 70 degrees
• No good overall correlation between P pulmonale and right atrial enlargement
• Severity of COPD is more related to rightward P wave axis than to P wave amplitude
Chamber Enlargement & Hypertrophy 21
P wave in the frontal leads is notched and the first component is increased in
amplitude and taller than the second component- reflects biatrial enlargement.
Chamber Enlargement & Hypertrophy 22
‘P’ TRICUSPIDALE
• Giant P waves-classically described in ebstein’s anomaly, also reported in Tricuspid atresia,
combined tricuspid and pulmonic stenosis. Best seen in leads II, III, aVF and V1
Chamber Enlargement & Hypertrophy 23
HIMALAYAN ‘P’ WAVES
• Tall peaked P waves in inferior leads in absence of right atrial enlargement. Seen in hypertensive
heart disease with/without heart failure .
• Actually reflects Left atrial enlargement due to increase in the later P-wave forces without
prolongation of atrial depolarisation.
Chamber Enlargement & Hypertrophy 24
PSEUDO ‘P’ PULMONALE
• (C) P mitrale - increase in the left atrial component in
amplitude and duration. Associated intraatrial
Conduction defect - prolongation of P wave duration
Chamber Enlargement & Hypertrophy 25
PSEUDO ‘P’ PULMONALE
• (D) Pseudo P pulmonale pattern in left atrial
enlargement. The amplitude of the left atrial
component is increased without increase in duration of
left atrial depolarization.
BIATRIAL ENLARGEMENT
• Large biphasic P wave in V1 initial component> 1.5 mm in height
and terminal component >1 mm in depth and 0.04 sec in duration.
• ‘P’ wave amplitude of more than 2.5 m and duration of more than
0.12 sec in lead II.
Chamber Enlargement & Hypertrophy 26
 MS/ MR with PAH
 MS/ MR with TS/TR
 ASD with PAH
 Lutembacher's
syndrome
 DCM/RCM
Atrial Fibrillation, itself indicates possible dilatation of the
atria in most disease.
Course ‘f’ waves in lead V1 (>1 mm) were associated with
radiological and anatomical evidence of atrial enlargement.
Chamber Enlargement & Hypertrophy 27
Ventricular Hypertrophy
• Age: QRS voltages decline with age. The commonly used voltage criteria
apply to adults > 35 years
• Gender: women have slightly lower voltages Race: Blacks have higher
voltages, hispanics and caucasians lower compared to whites
• Body Habitus
Chamber Enlargement & Hypertrophy 28
Mechanisms of ECG changes
• Prolongation of action potential duration
• Increased transmural activation time
• Change in cardiac position with LV dilatation
• Brody effect
• Secondary ST-T chamges possibly due to subendocardial ischemia ( the
term 'strain' is to be avoided)
Chamber Enlargement & Hypertrophy 29
Chamber Enlargement & Hypertrophy 30
Ventricular Activation Time
• Indicator of transverse conduction
time across LV wall
• Prolonged in LVH (normal <4Oms
in Left leads, <20ms in right leads)
CLASSIFICATION OF LV
ENLARGEMENT
LV VOLUME
LV MASS
COMMENT
S
NORMAL
ABNORMA
L
NORMAL NORMAL
CONCENTRIC
LVH
Abnormal
Volume >
90ml/m2
ABNORMAL
ISOLATED LV
VOLUME
OVERLOAD
ECCENTRIC
COMMENTS
Abnormal LV mass > 131g/ m2 in males,
108 g/m2 in females.
Chamber Enlargement & Hypertrophy 31
• T wave inverted in left oriented leads V5, V6, I, AVL and upright in V1, V2, AVR.
• Inverted T wave - blunt apex, asymmetrical limb, the proximal limb is shallower than distal limb.
• Associated ST segment is minimally depressed with slight upward convexity
Chamber Enlargement & Hypertrophy 32
LVH WITH PRESSURE OVERLOAD
• Deep and narrow Q waves in left oriented leads V5, V6.
• The tall T waves in left precordial leads V5, V6 are symmetrical sharply pointed.
• ST segment in V5, V6 minimally elevated and concavity upwards.
Chamber Enlargement & Hypertrophy 33
LVH WITH DIASTOLIC OVERLOAD
DIASTOLIC OVERLOAD IN AR &
MR
• Diastolic overload of MR can be distinguished by ECG from AR.
• In MR, Giant LA will displace the heart forward, QRS vector is
less aligned with V1 and more aligned with V6. Hence S wave in
lead V1 will be attenuated.
• In AR, the S wave in V1 is deep.
Chamber Enlargement & Hypertrophy 34
Sokolow Lyon Criteria (1949)
S in V1 + R in V5/V6 > 3.5 mv
OR
R in V5 or V6 > 2.60 mv.
Chamber Enlargement & Hypertrophy 35
Cornell voltage criteria (1987)
R in aVL +S in V3 > 2.80 mv for Males
Chamber Enlargement & Hypertrophy 36
Cornell voltage-duration product
• QRS duration x Cornell voltage >244 mVms
• QRS duration x sum of voltages in all leads >1742 mm-
sec
• R in aVL >11 mm.
• RI+SIII > 25 mm.
• Total 12 lead voltage >175 mm
LVH IN THE PRESENCE OF
CONDUCTION DISORDERS:
RBBB (reduces the S wave in the precordial leads)
Chamber Enlargement & Hypertrophy 37
LVH IN THE PRESENCE OF
CONDUCTION DISORDERS:
LAFB (QRS vector shifts posteriorly)
Chamber Enlargement & Hypertrophy 38
LVH IN THE PRESENCE OF
CONDUCTION DISORDERS:
LBBB
Chamber Enlargement & Hypertrophy 39
• LVH and LBBB share a number of common features like
prolonged QRS duration and voltage.
• Criteria for LVH are most unreliable in the presence of
LBBB.
• LBBB itself is indicative of LVH in most cases.
• Klein et al, Using echocardiograms found that in the
presence of LBBB S V2 + R V6 > 45 mm.
• E/o LAE with QRS duration > 0.16.
Significance
Chamber Enlargement & Hypertrophy 40
• LVH on ECG correlated with increased CV mortality
• LIFE study showed improvement in survival with LVH regression
(Cornell criterion), also HOPE trial (Sokolow Lyon criteria)
• Secondary ST-T changes and associated LAE indicate worse
prognosis
• Prominent ST T changes in apical hypertrophy (Yamaguchi
syndrome)
• Cornell product is one of the best predictors of overall outcome
Right Ventricular Hypertrophy
• The right ventricle is considerably smaller than the left ventricle.
• For RV forces to be manifested on the ECG, they must be severe
enough to overcome the concealing effects of the larger LV forces.
• In mild RVH, the ECG may be normal or there may only be a shift of
QRS axis.
Chamber Enlargement & Hypertrophy 41
ECG Criteria for RVH
• The ECG is notoriously inadequate in detecting RVH
• Its sensitivity is in the range of 2%-18% but it is very
specific (90%)
• Vectorial classification of RVH (Chou and Helm, 1967)
• Type A: R in V1, S in V6 (CCW loop) - PS
• Type B: R/S>1 in Vi with R> 0.5m V (CW loop) - RHD MS
• Type C :S in V5-6. with R/S<1 in V5, CW loop - COPD
Chamber Enlargement & Hypertrophy 42
• Leads aVR, V1, and V2- abnormally tall R waves.
• I, aVL, V5, V6- Deep S waves leading to RS or rS complex
• Right axis deviation
Chamber Enlargement & Hypertrophy 43
RVH WITH PRESSURE OVERLOAD
Sokolow Lyon Criteria (1949)
• R in V1 + S in V5/V6 > 1.10 mV
• R in V1 > 0.7 mV
• S wave in V5 or V6 > 0.7 mV
• qR in V1
• R/S ratio in V1 > 1 with R >0.5 mV
• R/S ratio of < 1 in V5 or V6
Chamber Enlargement & Hypertrophy 44
CAUSES OF RVH
• Systolic (pressure) overload
• Pulmonary Stenosis
• Pulmonary Hypertension
• TOF (unusual feature - no ‘strain’ pattern)
• Diastolic (volume) overload
• ASD/ TAPVC/ PAPVC
Chamber Enlargement & Hypertrophy 45
• In lead V1 -tall monophasic R wave or a diphasic RS, Rs, or qR Compleex.
• Inversion in right precordial leads ('strain)
• S pattern in V6
• In pure valvular PS, age 2-20, height of R wave in mm multiplied by 5gives RV systolic pressure
Chamber Enlargement & Hypertrophy 46
• Pattern of incomplete or complete RBBB
• RVH is present if R in the precordial leads is greater than 10 mm in height in
• incomplete RBBB, and 15 mm in complete RBBB- Barker & Valencia criteria
Chamber Enlargement & Hypertrophy 47
RVH WITH RBBB
V1
• Normal young adult
• True posterior infarction
• Dextrocardia
• LPFB
• Displacement of the heart due to pulmonary disease
• Wolff Parkinson White pattern
• Muscular dystrophy
Chamber Enlargement & Hypertrophy 48
BIVENTRICULAR HYPERTROPHY
Hypertrophy of both ventricles produces complex
electrocardiographic patterns. Not the simple sum of the two
sets of abnormalities. The effects of enlargement of one
chamber may cancel the effects of enlargement of the other.
Chamber Enlargement & Hypertrophy 49
• LVH +Prominent R waves in right precordial leads.
• Voltage criteria for LVH + RAD
• LAE as sole criterion for LVH + RVH.
• ECG evidence of LVH with clockwise rotation of
heart.
• Large equiphasic QRS complex in mid precordial
leads.
• CHAMBER ENLARGEMENT IN
PEDIATRIC AGE GROUP
• Related to changes in LV:RV mass.
• Birth: RV is thicker than LV.
• Large increase in LV weight during
first month.
• LV:RV reaches 2:1 by 6 months of
age.
• LV:RV WEIGHT RATIO
o At birth - 0.8:1
o 1 month - 1.5:1
o 6 months - 2.0:1
o Adult - 2.5:1
Chamber Enlargement & Hypertrophy 50
ATRIAL ABNORMALITY
• RAA - Peaked P wave in leads II and V1
• 3 mm in infants < 6 months
• 2.5 mm in infants > 6 months.
• LAA - Prolongation of P wave duration
• 12 mths->0.10 sec.
• <12 mths ->0.08 sec.
• Terminal or deeply inverted p waves in V1 or V3R
Chamber Enlargement & Hypertrophy 51
RVH
R wave greater than the 98th percentile in lead V1.
S wave greater than the 98th percentile in lead I or V6.
RSR' - pattern in lead V1,
R' height > 15 mm in infants less than 1 year or
R' height > 10 mm in Children's more than 1 year.
Upright T waves in V1 (> 7 days, up to 10 years)
qR pattern in V1
Overall sensitivity 69%, specificity 82%.
Chamber Enlargement & Hypertrophy 52
LVH
• R-wave amplitude greater than
98th percentile in lead V5 or V6.
• R wave less than 5th Percentile
in lead V1 or V2.
• S-wave amplitude greater than
98th percentile in lead V1.
• Q wave greater than 4 mm in
lead V5 or V6 Inverted T wave in
lead V6 Chamber Enlargement & Hypertrophy 53
Suggested Reading
An Introduction to
Electrocardiography -Leo
Schamroth 7th ed
AHA/ ACCF/ HRS
recommendations for the
standardisation and
interpretation of the
Electrocardiogram Part V.
JACC 2009; 53: 992-1002
Marriott's Practical
Electrocardiography 11thed
Cardiology Clinics August
2006
Advanced 12-lead
Electrocardiography;
Chamber Enlargement & Hypertrophy 54
Thank you.

Contenu connexe

Tendances

Echo Mitral Stenosis
Echo Mitral StenosisEcho Mitral Stenosis
Echo Mitral StenosisMashiul Alam
 
Echocardiography in ischemic heart disease
Echocardiography in ischemic heart diseaseEchocardiography in ischemic heart disease
Echocardiography in ischemic heart diseaseBhargav Kiran
 
Echo assessment of Aortic Regurgitation
Echo assessment of Aortic RegurgitationEcho assessment of Aortic Regurgitation
Echo assessment of Aortic RegurgitationMashiul Alam
 
Ecg criteria of chamber enlargement
Ecg criteria of chamber enlargementEcg criteria of chamber enlargement
Ecg criteria of chamber enlargementAdarsh
 
Basics of echo & principles of doppler echocardiography
Basics of echo & principles of doppler echocardiographyBasics of echo & principles of doppler echocardiography
Basics of echo & principles of doppler echocardiographyabrahahailu
 
Diastolic Dysfunction 2016
Diastolic Dysfunction 2016Diastolic Dysfunction 2016
Diastolic Dysfunction 2016drabhishekbabbu
 
Dobutamine stress echocardiography
Dobutamine stress echocardiographyDobutamine stress echocardiography
Dobutamine stress echocardiographyHimanshu Rana
 
ECG diagnosis of chamber enlargement
ECG diagnosis of  chamber enlargement ECG diagnosis of  chamber enlargement
ECG diagnosis of chamber enlargement Magesh Vadivelu
 
ventricular tachycardia (VT) Localisation
ventricular tachycardia (VT) Localisationventricular tachycardia (VT) Localisation
ventricular tachycardia (VT) LocalisationMalleswara rao Dangeti
 
Echo in ischaemic heart disease and Myocardial infarction
Echo in ischaemic heart disease and Myocardial infarctionEcho in ischaemic heart disease and Myocardial infarction
Echo in ischaemic heart disease and Myocardial infarctionNizam Uddin
 
Ecg changes in chamber enlargement
Ecg changes in chamber enlargementEcg changes in chamber enlargement
Ecg changes in chamber enlargementAnirudhya J
 
MVP Mitral Valve Prolapse - Echocardiographic Evaluation
 MVP Mitral Valve  Prolapse - Echocardiographic Evaluation MVP Mitral Valve  Prolapse - Echocardiographic Evaluation
MVP Mitral Valve Prolapse - Echocardiographic EvaluationPraveen Nagula
 
electrocardiogram (Ecg) in CONGENITAL HEART DISEASES
electrocardiogram (Ecg) in CONGENITAL HEART DISEASESelectrocardiogram (Ecg) in CONGENITAL HEART DISEASES
electrocardiogram (Ecg) in CONGENITAL HEART DISEASESMalleswara rao Dangeti
 
Echocardiographic evaluation of lv function
Echocardiographic evaluation of lv functionEchocardiographic evaluation of lv function
Echocardiographic evaluation of lv functionNguyen Phong Trung
 

Tendances (20)

Echo Mitral Stenosis
Echo Mitral StenosisEcho Mitral Stenosis
Echo Mitral Stenosis
 
Echocardiography in ischemic heart disease
Echocardiography in ischemic heart diseaseEchocardiography in ischemic heart disease
Echocardiography in ischemic heart disease
 
Echo assessment of Aortic Regurgitation
Echo assessment of Aortic RegurgitationEcho assessment of Aortic Regurgitation
Echo assessment of Aortic Regurgitation
 
Ecg criteria of chamber enlargement
Ecg criteria of chamber enlargementEcg criteria of chamber enlargement
Ecg criteria of chamber enlargement
 
Basics of echo & principles of doppler echocardiography
Basics of echo & principles of doppler echocardiographyBasics of echo & principles of doppler echocardiography
Basics of echo & principles of doppler echocardiography
 
CATH MEET PDA
CATH MEET PDACATH MEET PDA
CATH MEET PDA
 
Atrial enlargement
Atrial enlargementAtrial enlargement
Atrial enlargement
 
Speckle tracking ans strain
Speckle tracking ans strainSpeckle tracking ans strain
Speckle tracking ans strain
 
Diastolic Dysfunction 2016
Diastolic Dysfunction 2016Diastolic Dysfunction 2016
Diastolic Dysfunction 2016
 
Dobutamine stress echocardiography
Dobutamine stress echocardiographyDobutamine stress echocardiography
Dobutamine stress echocardiography
 
ECG diagnosis of chamber enlargement
ECG diagnosis of  chamber enlargement ECG diagnosis of  chamber enlargement
ECG diagnosis of chamber enlargement
 
ventricular tachycardia (VT) Localisation
ventricular tachycardia (VT) Localisationventricular tachycardia (VT) Localisation
ventricular tachycardia (VT) Localisation
 
cath Lab Hemoduhynamic
cath Lab Hemoduhynamiccath Lab Hemoduhynamic
cath Lab Hemoduhynamic
 
Echo in ischaemic heart disease and Myocardial infarction
Echo in ischaemic heart disease and Myocardial infarctionEcho in ischaemic heart disease and Myocardial infarction
Echo in ischaemic heart disease and Myocardial infarction
 
Ecg changes in chamber enlargement
Ecg changes in chamber enlargementEcg changes in chamber enlargement
Ecg changes in chamber enlargement
 
HOCM Hypertrophic cardiomyopathy
HOCM Hypertrophic cardiomyopathyHOCM Hypertrophic cardiomyopathy
HOCM Hypertrophic cardiomyopathy
 
MVP Mitral Valve Prolapse - Echocardiographic Evaluation
 MVP Mitral Valve  Prolapse - Echocardiographic Evaluation MVP Mitral Valve  Prolapse - Echocardiographic Evaluation
MVP Mitral Valve Prolapse - Echocardiographic Evaluation
 
electrocardiogram (Ecg) in CONGENITAL HEART DISEASES
electrocardiogram (Ecg) in CONGENITAL HEART DISEASESelectrocardiogram (Ecg) in CONGENITAL HEART DISEASES
electrocardiogram (Ecg) in CONGENITAL HEART DISEASES
 
Left atrial function
Left atrial functionLeft atrial function
Left atrial function
 
Echocardiographic evaluation of lv function
Echocardiographic evaluation of lv functionEchocardiographic evaluation of lv function
Echocardiographic evaluation of lv function
 

Similaire à Chamber Enlargement & Hypertrophy: ECG Criteria

Similaire à Chamber Enlargement & Hypertrophy: ECG Criteria (20)

The ECG in chmaber enlargement final.pptx
The ECG in chmaber enlargement final.pptxThe ECG in chmaber enlargement final.pptx
The ECG in chmaber enlargement final.pptx
 
cases of ecg interpretation
 cases of ecg interpretation cases of ecg interpretation
cases of ecg interpretation
 
ECG BY Dr.MOHAMED RAMADAN
ECG BY Dr.MOHAMED RAMADANECG BY Dr.MOHAMED RAMADAN
ECG BY Dr.MOHAMED RAMADAN
 
E C G M O H A M E D R A M A D A N
E C G  M O H A M E D  R A M A D A NE C G  M O H A M E D  R A M A D A N
E C G M O H A M E D R A M A D A N
 
The ecg in chmaber enlargement approach
The ecg in chmaber enlargement approachThe ecg in chmaber enlargement approach
The ecg in chmaber enlargement approach
 
Complete EKG Interpretation Course
Complete EKG Interpretation Course Complete EKG Interpretation Course
Complete EKG Interpretation Course
 
Pe
PePe
Pe
 
Basic ecg
Basic ecgBasic ecg
Basic ecg
 
Tutorial in ecg
Tutorial in ecgTutorial in ecg
Tutorial in ecg
 
Basics of ecg
Basics of ecgBasics of ecg
Basics of ecg
 
44 E C G
44 E C G44 E C G
44 E C G
 
44 E C G
44 E C G44 E C G
44 E C G
 
Hocm
HocmHocm
Hocm
 
cardiac hypertrophy
cardiac hypertrophycardiac hypertrophy
cardiac hypertrophy
 
Ecgrevised2 090808155046 Phpapp01
Ecgrevised2 090808155046 Phpapp01Ecgrevised2 090808155046 Phpapp01
Ecgrevised2 090808155046 Phpapp01
 
Ecg interpretation
Ecg interpretationEcg interpretation
Ecg interpretation
 
Pediatric ecg
Pediatric ecgPediatric ecg
Pediatric ecg
 
ECG BASICS IN DETAIL
ECG BASICS IN DETAILECG BASICS IN DETAIL
ECG BASICS IN DETAIL
 
Ecg
EcgEcg
Ecg
 
Ecg basics
Ecg basicsEcg basics
Ecg basics
 

Plus de Kunal Ajay Patankar

Plus de Kunal Ajay Patankar (10)

GROWTH PREDICTION -II.pptx
GROWTH PREDICTION -II.pptxGROWTH PREDICTION -II.pptx
GROWTH PREDICTION -II.pptx
 
Growth Prediction part 1.pptx
Growth Prediction part 1.pptxGrowth Prediction part 1.pptx
Growth Prediction part 1.pptx
 
Elastics in Orthodontics-II
Elastics in Orthodontics-IIElastics in Orthodontics-II
Elastics in Orthodontics-II
 
Elastics in Orthodontics -part I
Elastics in Orthodontics -part IElastics in Orthodontics -part I
Elastics in Orthodontics -part I
 
Clear aligner part ii
Clear aligner part iiClear aligner part ii
Clear aligner part ii
 
Clear aligner treatment
Clear aligner treatmentClear aligner treatment
Clear aligner treatment
 
Orthodontic treatment planning
Orthodontic treatment planning Orthodontic treatment planning
Orthodontic treatment planning
 
Assessment of growth and development.
Assessment of growth and development.Assessment of growth and development.
Assessment of growth and development.
 
Growth and development of facial structures
Growth and development of facial structures Growth and development of facial structures
Growth and development of facial structures
 
Orthopaedic appliance seminar
Orthopaedic appliance seminarOrthopaedic appliance seminar
Orthopaedic appliance seminar
 

Dernier

microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfsanyamsingh5019
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
social pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajansocial pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajanpragatimahajan3
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionSafetyChain Software
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformChameera Dedduwage
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
JAPAN: ORGANISATION OF PMDA, PHARMACEUTICAL LAWS & REGULATIONS, TYPES OF REGI...
JAPAN: ORGANISATION OF PMDA, PHARMACEUTICAL LAWS & REGULATIONS, TYPES OF REGI...JAPAN: ORGANISATION OF PMDA, PHARMACEUTICAL LAWS & REGULATIONS, TYPES OF REGI...
JAPAN: ORGANISATION OF PMDA, PHARMACEUTICAL LAWS & REGULATIONS, TYPES OF REGI...anjaliyadav012327
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13Steve Thomason
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Disha Kariya
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxGaneshChakor2
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 

Dernier (20)

microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdf
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
social pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajansocial pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajan
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory Inspection
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
JAPAN: ORGANISATION OF PMDA, PHARMACEUTICAL LAWS & REGULATIONS, TYPES OF REGI...
JAPAN: ORGANISATION OF PMDA, PHARMACEUTICAL LAWS & REGULATIONS, TYPES OF REGI...JAPAN: ORGANISATION OF PMDA, PHARMACEUTICAL LAWS & REGULATIONS, TYPES OF REGI...
JAPAN: ORGANISATION OF PMDA, PHARMACEUTICAL LAWS & REGULATIONS, TYPES OF REGI...
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptx
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 

Chamber Enlargement & Hypertrophy: ECG Criteria

  • 2. Role of ECG • ECG is a simple, readily available and inexpensive tool for the detection of cardiac chamber enlargement • Can provide useful clues or arouse suspicion of underlying cardiac condition • Most ECCG criteria have low sensitivity but high specificity • Clinical correlates and prognostic significance • Screening and population based studies Chamber Enlargement & Hypertrophy 2
  • 3. General Principles • Enlargement of the cardiac Chambers may manifest on the ECG as an alteration of • Waveform morphology • Amplitude / Voltage • Axis • Duration (widening) • These applied to both the p waves and the QRS complex • Atrial abnormalities may suggest corresponding ventricular hypertrophy Chamber Enlargement & Hypertrophy 3
  • 4. Limitations • Enlargement? hypertrophy? dilatation? • Voltage criteria can carry significantly based on • Age • Gender • Race • Habitus (chest wall thickness/abnormalities ) • Pulmonary/pericardial pathology Chamber Enlargement & Hypertrophy 4
  • 5. Before commenting • Assess technical quality of ECG • Placement of the electrolytes (especially precordial) • Voltage standardisation (1 mm=0.1 millivolt) • SPEED of recording (can affect measurement of duration) • Preferable to express voltage in millivolts (mV) rather than millimeter (mm) Chamber Enlargement & Hypertrophy 5
  • 6. Atrial abnormalities Atrial dilatation, hypertrophic, elevated atrial pressures, impaired ventricular distensibility, and delayed intra-atrial conduction produced similar changes on ECG and cannot be differentiated As such, the terms of left atrial abnormality in right atrial abnormality or preferably to left / right atrial enlargement, the mitrale / congenitale / pulmonale Chamber Enlargement & Hypertrophy 6
  • 8. Chamber Enlargement & Hypertrophy 8 P wave reflects atrial depolarisation Right atrial activation begins first. Proceeds from the SAN into (sinoatrial node) in the inferior and the anterior direction and is reflected by ascending limb of the p wave in the frontal plane leads.
  • 9. Chamber Enlargement & Hypertrophy 9 Left atrial activation begins 0.03 seconds after the right atrial activation. Proceeds from high in the interatrial septum (IAS) in a left, inferior and posterior direction. Constitute distal half of the descending limb of the p wave.
  • 10. Normal ‘P’ wave LEAD II Duration in lead II is 0.08 - 0.1 second, Max 0. 11 second. Amplitude in lead: Usually 2 mm, max 2.5 mm. Chamber Enlargement & Hypertrophy 10 LEAD V1 Usually biphasic. Initial positive movement deflection < 1.5 mm Terminal negative deflection not exceeding 1 mm in-depth and < 0.03 seconds in duration. Duration of p wave in V1 is 0.05-0.08 second.
  • 11. Left atrial abnormalities 3 basic ECG changes: 1. Prolongation and delay of the terminal or left atrial component of atrial activation (Bachmann’s bundle). 2. Increased posterior deviation of left atrial vector 3. Left axis deviation of main manifest frontal plane p wave axis. Chamber Enlargement & Hypertrophy 11
  • 12. Criteria for LAA LEAD II Chamber Enlargement & Hypertrophy 12 LEAD V1 – P terminal force (MORRIS Index) • Ratio between the duration of p wave in lead II and the PR segment of >1.6 (Marcuz Index) • Leftward shift of the p wave axis less than 15-30°
  • 13. ECHOCARDIOGRAPHIC EVALUATION OF ECG CRITERIA FOR LAA CRITERA SENSITIVITY SPECIFICITY Terminal negative P in V1 >0.04 mm-sec 83 80 Duration between peak of P Wave notches > 0.04 s 15 100 P wave duration >0.11 s 31 64 Ratio of P wave duration to PR segment> 1.6 31 64 Amplitude of terminal -ve P wave deflection in V1 > 0.1mv 60 93 Chamber Enlargement & Hypertrophy 13
  • 14. CAUSES OF LA ABNORMALITY • Valvular heart disease, mainly mitral and aortic • Hypertensive heart disease • Cardiomyopathy (dilated/ restrictive/hypertrophic) • CAD Chamber Enlargement & Hypertrophy 14
  • 15. • The term P mitrale refers to a P wave that is abnormally notched and wide because this P wave is commonly seen in patients with mitral valve disease, particularly mitral stenosis. Chamber Enlargement & Hypertrophy 15
  • 16. • The mere presence of a twin-peaked P wave is not diagnostic of LA abnormality Chamber Enlargement & Hypertrophy 16
  • 17. Right atrial abnormalities LEAD II • Total p wave duration is usually normal. • Peaked p waves with amplitudes in lead to more than 0.25 millivolts (even a normal amplitude p wave if pointed) LEAD V1 • Prominent initial positivity of the P wave in V1 or V2 (>0.15 mV) • Initial area under curve >0.06 mm-sec qR complex, namely a small q followed by a large R wave, usually in tricuspid regurgitation • Low-amplitude (<0.6 mV) QRS complexes in lead V1 with a threefold or greater increase in lead V2 Chamber Enlargement & Hypertrophy 17
  • 18. Change in ‘P’ axis • In acquired heart disease (e.g. COPD), rightward shift of the mean P wave axis to above +75 degrees – ‘P pulmonale’ • In congenital heart disease, the axis is normal or to left (-40 to +70 degrees) – ‘P congenitale’ Chamber Enlargement & Hypertrophy 18
  • 19. Kaplan Criteria • QRS axis> 90° • P amplitude in V2> 0.15mv • R/S> 1 in V1 in the absence of RBBB • Combined sensitivity of 49% with specificity of 100% Chamber Enlargement & Hypertrophy 19
  • 20. CAUSES OF RA ABNORMALITY • Congenital heart disease (Ebstein's anomaly, severe PS) • Tricuspid valve disease • Chronic cor pulmonale (COPD) RAA is very uncommon in isolated ASD without PH. Chamber Enlargement & Hypertrophy 20
  • 21. • Tall, peaked ("gothic") P wave in leads IIL, IIL, and aVF ,P axis> 70 degrees • No good overall correlation between P pulmonale and right atrial enlargement • Severity of COPD is more related to rightward P wave axis than to P wave amplitude Chamber Enlargement & Hypertrophy 21
  • 22. P wave in the frontal leads is notched and the first component is increased in amplitude and taller than the second component- reflects biatrial enlargement. Chamber Enlargement & Hypertrophy 22 ‘P’ TRICUSPIDALE
  • 23. • Giant P waves-classically described in ebstein’s anomaly, also reported in Tricuspid atresia, combined tricuspid and pulmonic stenosis. Best seen in leads II, III, aVF and V1 Chamber Enlargement & Hypertrophy 23 HIMALAYAN ‘P’ WAVES
  • 24. • Tall peaked P waves in inferior leads in absence of right atrial enlargement. Seen in hypertensive heart disease with/without heart failure . • Actually reflects Left atrial enlargement due to increase in the later P-wave forces without prolongation of atrial depolarisation. Chamber Enlargement & Hypertrophy 24 PSEUDO ‘P’ PULMONALE
  • 25. • (C) P mitrale - increase in the left atrial component in amplitude and duration. Associated intraatrial Conduction defect - prolongation of P wave duration Chamber Enlargement & Hypertrophy 25 PSEUDO ‘P’ PULMONALE • (D) Pseudo P pulmonale pattern in left atrial enlargement. The amplitude of the left atrial component is increased without increase in duration of left atrial depolarization.
  • 26. BIATRIAL ENLARGEMENT • Large biphasic P wave in V1 initial component> 1.5 mm in height and terminal component >1 mm in depth and 0.04 sec in duration. • ‘P’ wave amplitude of more than 2.5 m and duration of more than 0.12 sec in lead II. Chamber Enlargement & Hypertrophy 26  MS/ MR with PAH  MS/ MR with TS/TR  ASD with PAH  Lutembacher's syndrome  DCM/RCM
  • 27. Atrial Fibrillation, itself indicates possible dilatation of the atria in most disease. Course ‘f’ waves in lead V1 (>1 mm) were associated with radiological and anatomical evidence of atrial enlargement. Chamber Enlargement & Hypertrophy 27
  • 28. Ventricular Hypertrophy • Age: QRS voltages decline with age. The commonly used voltage criteria apply to adults > 35 years • Gender: women have slightly lower voltages Race: Blacks have higher voltages, hispanics and caucasians lower compared to whites • Body Habitus Chamber Enlargement & Hypertrophy 28
  • 29. Mechanisms of ECG changes • Prolongation of action potential duration • Increased transmural activation time • Change in cardiac position with LV dilatation • Brody effect • Secondary ST-T chamges possibly due to subendocardial ischemia ( the term 'strain' is to be avoided) Chamber Enlargement & Hypertrophy 29
  • 30. Chamber Enlargement & Hypertrophy 30 Ventricular Activation Time • Indicator of transverse conduction time across LV wall • Prolonged in LVH (normal <4Oms in Left leads, <20ms in right leads)
  • 31. CLASSIFICATION OF LV ENLARGEMENT LV VOLUME LV MASS COMMENT S NORMAL ABNORMA L NORMAL NORMAL CONCENTRIC LVH Abnormal Volume > 90ml/m2 ABNORMAL ISOLATED LV VOLUME OVERLOAD ECCENTRIC COMMENTS Abnormal LV mass > 131g/ m2 in males, 108 g/m2 in females. Chamber Enlargement & Hypertrophy 31
  • 32. • T wave inverted in left oriented leads V5, V6, I, AVL and upright in V1, V2, AVR. • Inverted T wave - blunt apex, asymmetrical limb, the proximal limb is shallower than distal limb. • Associated ST segment is minimally depressed with slight upward convexity Chamber Enlargement & Hypertrophy 32 LVH WITH PRESSURE OVERLOAD
  • 33. • Deep and narrow Q waves in left oriented leads V5, V6. • The tall T waves in left precordial leads V5, V6 are symmetrical sharply pointed. • ST segment in V5, V6 minimally elevated and concavity upwards. Chamber Enlargement & Hypertrophy 33 LVH WITH DIASTOLIC OVERLOAD
  • 34. DIASTOLIC OVERLOAD IN AR & MR • Diastolic overload of MR can be distinguished by ECG from AR. • In MR, Giant LA will displace the heart forward, QRS vector is less aligned with V1 and more aligned with V6. Hence S wave in lead V1 will be attenuated. • In AR, the S wave in V1 is deep. Chamber Enlargement & Hypertrophy 34
  • 35. Sokolow Lyon Criteria (1949) S in V1 + R in V5/V6 > 3.5 mv OR R in V5 or V6 > 2.60 mv. Chamber Enlargement & Hypertrophy 35
  • 36. Cornell voltage criteria (1987) R in aVL +S in V3 > 2.80 mv for Males Chamber Enlargement & Hypertrophy 36 Cornell voltage-duration product • QRS duration x Cornell voltage >244 mVms • QRS duration x sum of voltages in all leads >1742 mm- sec • R in aVL >11 mm. • RI+SIII > 25 mm. • Total 12 lead voltage >175 mm
  • 37. LVH IN THE PRESENCE OF CONDUCTION DISORDERS: RBBB (reduces the S wave in the precordial leads) Chamber Enlargement & Hypertrophy 37
  • 38. LVH IN THE PRESENCE OF CONDUCTION DISORDERS: LAFB (QRS vector shifts posteriorly) Chamber Enlargement & Hypertrophy 38
  • 39. LVH IN THE PRESENCE OF CONDUCTION DISORDERS: LBBB Chamber Enlargement & Hypertrophy 39 • LVH and LBBB share a number of common features like prolonged QRS duration and voltage. • Criteria for LVH are most unreliable in the presence of LBBB. • LBBB itself is indicative of LVH in most cases. • Klein et al, Using echocardiograms found that in the presence of LBBB S V2 + R V6 > 45 mm. • E/o LAE with QRS duration > 0.16.
  • 40. Significance Chamber Enlargement & Hypertrophy 40 • LVH on ECG correlated with increased CV mortality • LIFE study showed improvement in survival with LVH regression (Cornell criterion), also HOPE trial (Sokolow Lyon criteria) • Secondary ST-T changes and associated LAE indicate worse prognosis • Prominent ST T changes in apical hypertrophy (Yamaguchi syndrome) • Cornell product is one of the best predictors of overall outcome
  • 41. Right Ventricular Hypertrophy • The right ventricle is considerably smaller than the left ventricle. • For RV forces to be manifested on the ECG, they must be severe enough to overcome the concealing effects of the larger LV forces. • In mild RVH, the ECG may be normal or there may only be a shift of QRS axis. Chamber Enlargement & Hypertrophy 41
  • 42. ECG Criteria for RVH • The ECG is notoriously inadequate in detecting RVH • Its sensitivity is in the range of 2%-18% but it is very specific (90%) • Vectorial classification of RVH (Chou and Helm, 1967) • Type A: R in V1, S in V6 (CCW loop) - PS • Type B: R/S>1 in Vi with R> 0.5m V (CW loop) - RHD MS • Type C :S in V5-6. with R/S<1 in V5, CW loop - COPD Chamber Enlargement & Hypertrophy 42
  • 43. • Leads aVR, V1, and V2- abnormally tall R waves. • I, aVL, V5, V6- Deep S waves leading to RS or rS complex • Right axis deviation Chamber Enlargement & Hypertrophy 43 RVH WITH PRESSURE OVERLOAD
  • 44. Sokolow Lyon Criteria (1949) • R in V1 + S in V5/V6 > 1.10 mV • R in V1 > 0.7 mV • S wave in V5 or V6 > 0.7 mV • qR in V1 • R/S ratio in V1 > 1 with R >0.5 mV • R/S ratio of < 1 in V5 or V6 Chamber Enlargement & Hypertrophy 44
  • 45. CAUSES OF RVH • Systolic (pressure) overload • Pulmonary Stenosis • Pulmonary Hypertension • TOF (unusual feature - no ‘strain’ pattern) • Diastolic (volume) overload • ASD/ TAPVC/ PAPVC Chamber Enlargement & Hypertrophy 45
  • 46. • In lead V1 -tall monophasic R wave or a diphasic RS, Rs, or qR Compleex. • Inversion in right precordial leads ('strain) • S pattern in V6 • In pure valvular PS, age 2-20, height of R wave in mm multiplied by 5gives RV systolic pressure Chamber Enlargement & Hypertrophy 46
  • 47. • Pattern of incomplete or complete RBBB • RVH is present if R in the precordial leads is greater than 10 mm in height in • incomplete RBBB, and 15 mm in complete RBBB- Barker & Valencia criteria Chamber Enlargement & Hypertrophy 47 RVH WITH RBBB
  • 48. V1 • Normal young adult • True posterior infarction • Dextrocardia • LPFB • Displacement of the heart due to pulmonary disease • Wolff Parkinson White pattern • Muscular dystrophy Chamber Enlargement & Hypertrophy 48
  • 49. BIVENTRICULAR HYPERTROPHY Hypertrophy of both ventricles produces complex electrocardiographic patterns. Not the simple sum of the two sets of abnormalities. The effects of enlargement of one chamber may cancel the effects of enlargement of the other. Chamber Enlargement & Hypertrophy 49 • LVH +Prominent R waves in right precordial leads. • Voltage criteria for LVH + RAD • LAE as sole criterion for LVH + RVH. • ECG evidence of LVH with clockwise rotation of heart. • Large equiphasic QRS complex in mid precordial leads.
  • 50. • CHAMBER ENLARGEMENT IN PEDIATRIC AGE GROUP • Related to changes in LV:RV mass. • Birth: RV is thicker than LV. • Large increase in LV weight during first month. • LV:RV reaches 2:1 by 6 months of age. • LV:RV WEIGHT RATIO o At birth - 0.8:1 o 1 month - 1.5:1 o 6 months - 2.0:1 o Adult - 2.5:1 Chamber Enlargement & Hypertrophy 50
  • 51. ATRIAL ABNORMALITY • RAA - Peaked P wave in leads II and V1 • 3 mm in infants < 6 months • 2.5 mm in infants > 6 months. • LAA - Prolongation of P wave duration • 12 mths->0.10 sec. • <12 mths ->0.08 sec. • Terminal or deeply inverted p waves in V1 or V3R Chamber Enlargement & Hypertrophy 51
  • 52. RVH R wave greater than the 98th percentile in lead V1. S wave greater than the 98th percentile in lead I or V6. RSR' - pattern in lead V1, R' height > 15 mm in infants less than 1 year or R' height > 10 mm in Children's more than 1 year. Upright T waves in V1 (> 7 days, up to 10 years) qR pattern in V1 Overall sensitivity 69%, specificity 82%. Chamber Enlargement & Hypertrophy 52
  • 53. LVH • R-wave amplitude greater than 98th percentile in lead V5 or V6. • R wave less than 5th Percentile in lead V1 or V2. • S-wave amplitude greater than 98th percentile in lead V1. • Q wave greater than 4 mm in lead V5 or V6 Inverted T wave in lead V6 Chamber Enlargement & Hypertrophy 53
  • 54. Suggested Reading An Introduction to Electrocardiography -Leo Schamroth 7th ed AHA/ ACCF/ HRS recommendations for the standardisation and interpretation of the Electrocardiogram Part V. JACC 2009; 53: 992-1002 Marriott's Practical Electrocardiography 11thed Cardiology Clinics August 2006 Advanced 12-lead Electrocardiography; Chamber Enlargement & Hypertrophy 54